Yury A. Surovoy

Immunoassay for Colistin Monitoring in Critically Ill Patients Receiving Colistin Methanesulfonate Therapy

Yury A. Surovoy, Inna A. Galvidis, Akmal I. Alimov, Z P Wang et autres

Background/Objectives: Colistin (COL), administered as a prodrug colistimethate sodium (CMS), is commonly used to treat infections caused by multidrug-resistant Gram-negative bacteria in critically ill patients. Given high CMS instability, very complex and variable pharmacokinetics (PK) and high incidence of toxicity, therapeutic drug …

gb, ru, cn (code pays fourni par la source)

Gut Hi-C metagenomes of severe COVID-19 patients: bacteria and yeast involved in gut-lung axis

Anastasia Revel-Muroz, Ignat V. Sonets, Alexander S. Chistyakov, Petr A. Vasiluev et autres

ABSTRACT Antimicrobial resistance (AMR) poses a critical threat to global health, particularly in intensive care units, where vulnerable patients are frequently exposed to multidrug-resistant microorganisms. The human gut microbiome serves as a key reservoir for AMR genes, which can disseminate to other …

ru (code pays fourni par la source)

Validation of limited sampling strategies for polymyxin B therapeutic drug monitoring in critical care

Yury A. Surovoy, Inna A. Galvidis, Akmal I. Alimov, Sergei V. Tsarenko et autres

gb, ru (code pays fourni par la source)

The provision of echocardiography in critical care: a multi-centre survey of the UK and Crown Dependencies

Luke Flower, Alicia Waite, Adam Jonathan Boulton, Marcus Peck et autres

gb, us (code pays fourni par la source)

Therapeutic Monitoring of Vancomycin Implemented by Eremomycin ELISA

Inna A. Galvidis, Yury A. Surovoy, Vitaly R. Sharipov, Pavel D. Sobolev et autres

BACKGROUND/OBJECTIVES: Due to a narrow therapeutic window, side-effects, toxicities, and individual pharmacokinetics (PK) variability, WHO classifies vancomycin (VCM) as a "watch antibiotic" whose use should be monitored to improve clinical effectiveness. Availability and ease of use have made the immunoassay technique the …

ru, gb (code pays fourni par la source)

Hapten Synthesis, Antibody Generation, and Immunoassay Development for Linezolid Therapeutic Monitoring

Maksim A. Burkin, Alexander S. Tikhomirov, Yury A. Surovoy, Inna A. Galvidis

Linezolid (LNZ) is a broad-spectrum antibiotic used for the treatment of severe Gram+ infections. Significant pharmacokinetic variability in different groups of patients requires therapeutic drug monitoring (TDM) to ensure optimal therapy. This article presents the first description of the development of immunoanalytical …

ru, gb (code pays fourni par la source)

The use of echocardiography in the management of shock in critical care: a prospective, multi-centre, observational study

Luke Flower, Alicia Waite, Adam Jonathan Boulton, Marcus Peck et autres

gb, us, ie (code pays fourni par la source)

Production of antibody and development of enzyme-linked immunosorbent assay for therapeutic drug monitoring of eravacycline

Inna A. Galvidis, Anastasia G. Moshcheva, Yury A. Surovoy, Pavel D. Sobolev et autres

Eravacycline (ERC) was approved for clinical use in 2018. It is more potent than other tetracyclines and can overcome resistance, making it an attractive option for combating multidrug-resistant bacterial infections. Intensive pharmacokinetic (PK) studies are currently being conducted to ensure the effectiveness …

ru, gb (code pays fourni par la source)

Tigecycline Immunodetection Using Developed Group-Specific and Selective Antibodies for Drug Monitoring Purposes

Inna A. Galvidis, Yury A. Surovoy, Sergei V. Tsarenko, Maksim A. Burkin

Tigecycline (TGC), a third-generation tetracycline, is characterized by a more potent and broad antibacterial activity, and the ability to overcome different mechanisms of tetracycline resistance. TGC has proven to be of value in treatment of multidrug-resistant infections, but therapy can be complicated …

ru (code pays fourni par la source)

Comparative polymyxin B pharmacokinetics in critically ill patients with renal insufficiency and in continuous veno-venous hemodialysis

Yury A. Surovoy, Maksim A. Burkin, Inna A. Galvidis, Mikhail A. Sobolev et autres

ru (code pays fourni par la source)

Comparative polymyxin B pharmacokinetics in critically ill patients with renal insufficiency and in continuous veno-venous hemodialysis

Yury A. Surovoy, Maksim A. Burkin, Inna A. Galvidis, Mikhail A. Sobolev et autres

Abstract The aim of this study was to assess polymyxin B pharmacokinetics (PK) in patients with varying degrees of renal dysfunction and in patients, who require continuous veno-venous hemodialysis (CVVHD). The study enrolled 37 patients with sepsis, among whom 13 patients with …

ru (code pays fourni par la source)

Unbound serum polymyxin B in patients with sepsis: Detection approaches and limited sampling strategy for clinical practice and research

Inna A. Galvidis, Yury A. Surovoy, Gleb S. Perevoznyuk, Sergei V. Tsarenko et autres

ru (code pays fourni par la source)